CNBC
13 Jun 2026, 18:00 UTC · 3h ago
The Next Phase Of The Obesity Drug Race
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
CNBC
13 Jun 2026, 18:00 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Novo Nordisk and Eli Lilly have introduced GLP-1 obesity medications in pill form this year. — Oral delivery significantly increases patient accessibility and market penetration compared to injectables.
+0.60Companies such as Structure Therapeutics and Zealand Pharma are entering the market to compete for obesity drug market share. — Increased competition from new entrants may erode the pricing power and market dominance of the current leaders.
-0.30Which stocks this story touches
The company is expanding its product line with the introduction of GLP-1 pills.
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is expanding its product line with the introduction of GLP-1 pills.
The company is actively competing for market share in the growing obesity drug market.
The company is actively competing for market share in the growing obesity drug market.
[mutual] Both companies are introducing GLP-1 pills in the obesity drug market.
[mutual] Structure Therapeutics is fighting for market share against established players like Eli Lilly.
[mutual] Zealand Pharma is fighting for market share against established players like Eli Lilly.
[mutual] Structure Therapeutics is fighting for market share against established players like Novo Nordisk.
[mutual] Zealand Pharma is fighting for market share against established players like Novo Nordisk.
[mutual] Both companies are trying to fight for market share in the obesity drug market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
1h ago
